EDMONTON, Alberta – ORLANDO, Florida – February 12 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX platform technology, and Protean BioDiagnostics Inc. (Protean) announced today that the American Medical Association (AMA) has issued a new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for ClarityDX Prostate.
↧